Fulcrum Therapeutics, Inc. Common Stock Stock Prediction
AI-powered sentiment analysis and prediction trends for FULC, updated each market day.
FULC AI Sentiment
AI sees no strong directional signal for Fulcrum Therapeutics, Inc. Common Stock stock over the next 10 market days.
Prediction date: April 10, 2026
Subscribers see precise scores, buy/sell targets, and full analytics.
About Fulcrum Therapeutics, Inc. Common Stock
Fulcrum Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing small molecules for genetically defined rare diseases. Its product candidate, Pociredir, is an oral small molecule designed to induce fetal hemoglobin (HbF) and is in clinical development for sickle cell disease (SCD). The company completed dosing in the Phase 1b PIONEER trial evaluating pociredir in adults with SCD and reported clinical data showing clinically relevant HbF induction and improvements in markers of hemolysis and anemia. The company has also generated a pipeline of clinical-stage and pre-clinical programs targeting the root causes of rare genetic diseases.
Sector
Exchange
Market Cap
$526,807,653
Cap Tier
Employees
55
Headquarters
CAMBRIDGE, MA
Listed Since
July 18, 2019
Website
FULC Sentiment Trend — Last 30 Predictions
Sentiment zones: Bullish · Neutral · Bearish
FULC Volatility
Fulcrum Therapeutics, Inc. Common Stock has shown high price volatility over the last 5 trading days. High volatility means larger price swings — this can present both opportunity and risk for traders.
